| 產品描述： | Epetraborole (GSK2251052) hydrochloride is a novel leucyl-tRNA synthetase (LeuRS) inhibitor (IC50=0.31 μM), thereby inhibiting protein synthesis. Epetraborole hydrochloride can be used in multidrug-resistant gram-negative pathogens infection research |
| 靶點： |
IC50: 0.31 μM (LeuRS);Antibacterial |
| 體外研究： |
Epetraborole (0-32 μg/mL) shows anti-bacterial activity against key gram-negative aerobic and anaerobic pathogens and gram-positive anaerobes. Cell Viability Assay Cell Line: Anaerobes isolates Concentration: 0-32 μg/mL Incubation Time: Result: Showed MIC50/MIC90 for all anaerobes isolates tested of 2 and 4 μg/mL, respectively. |
| 參考文獻： |
1. Goldstein EJ, et al. Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms. Antimicrob Agents Chemother. 2013 May;57(5):2401-4. 2. O'Dwyer K, et al. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98. 3. Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci. 2011 Dec;1241:122-52. |
| 溶解性： |
Soluble in DMSO、H2O |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
3.656 ml |
18.28 ml |
36.56 ml |
| 5 mM |
0.731 ml |
3.656 ml |
7.312 ml |
| 10 mM |
0.366 ml |
1.828 ml |
3.656 ml |
| 50 mM |
0.073 ml |
0.366 ml |
0.731 ml |
|
| 注意： |
部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京